NasdaqGS:MLYSBiotechs
Did JAMA’s “Research of the Year” Nod for Launch-HTN Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative?
Mineralys Therapeutics recently announced that its Phase 3 Launch-HTN trial of lorundrostat for uncontrolled or treatment-resistant hypertension was selected for JAMA’s inaugural “Research of the Year Roundup,” highlighting it as one of the most impactful studies published between October 2024 and September 2025.
This recognition not only spotlights lorundrostat’s growing clinical profile but also underscores aldosterone’s emerging role as a key therapeutic target in difficult-to-treat...